This newsletter presents you the following key sessions:
1. IMpower010 highlights trend towards an overall survival benefit with atezolizumab in resected
stage II-IIIA NSCLC
2. Entrectinib confirms its overall and intracranial efficacy in patients with ROS1-fusion positive
metastatic NSCLC
3. Sub-lobar resection not inferior to lobectomy for peripheral cT1aN0 non-small cell lung cancer ≤ 2 cm
4. Avelumab not superior to chemotherapy as first-line treatment of advanced PD-L1 positive NSCLC
5. Talazoparib plus temozolomide for extensive-stage relapsed or refractory small cell lung cancer
